Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.

Article Details

Citation

Copy to clipboard

Wen X, Wang JS, Backman JT, Kivisto KT, Neuvonen PJ

Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.

Drug Metab Dispos. 2001 Nov;29(11):1359-61.

PubMed ID

11602509 [ View in PubMed

]

Abstract

The in vitro inhibitory effects of gemfibrozil on cytochrome P450 (CYP) 1A2 (phenacetin O-deethylation), CYP2A6 (coumarin 7-hydroxylation), CYP2C9 (tolbutamide hydroxylation), CYP2C19 (S-mephenytoin 4'-hydroxylation), CYP2D6 (dextromethorphan O-deethylation), CYP2E1 (chlorzoxazone 6-hydroxylation), and CYP3A4 (midazolam 1'-hydroxylation) activities were examined using pooled human liver microsomes. The in vivo drug interactions of gemfibrozil were predicted in vitro using the [I]/([I] + K(i)) values. Gemfibrozil strongly and competitively inhibited CYP2C9 activity, with a K(i) (IC(50)) value of 5.8 (9.6) microM. In addition, gemfibrozil exhibited somewhat smaller inhibitory effects on CYP2C19 and CYP1A2 activities, with K(i) (IC(50)) values of 24 (47) microM and 82 (136) microM, respectively. With concentrations up to 250 microM, gemfibrozil showed no appreciable effect on CYP2A6, CYP2D6, CYP2E1, and CYP3A4 activities. Based on [I]/([I] + K(i)) values calculated using peak total (or unbound) plasma concentration of gemfibrozil, 96% (56%), 86% (24%), and 64% (8%) inhibition of the clearance of CYP2C9, CYP2C19, and CYP1A2 substrates could be expected, respectively. In conclusion, gemfibrozil inhibits the activity of CYP2C9 at clinically relevant concentrations, and this is the likely mechanism by which gemfibrozil interacts with CYP2C9 substrate drugs, such as warfarin and glyburide. Gemfibrozil may also impair clearance of CYP2C19 and CYP1A2 substrates, but inhibition of other CYP isoforms is unlikely.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Gemfibrozil	Cytochrome P450 1A2	Protein	Humans	Unknown	Inhibitor	Details
Gemfibrozil	Cytochrome P450 2C19	Protein	Humans	Unknown	Inhibitor	Details
Gemfibrozil	Cytochrome P450 2C9	Protein	Humans	Unknown	Inhibitor	Details

Drug Interactions

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Acenocoumarol Etofibrate	The risk or severity of bleeding can be increased when Etofibrate is combined with Acenocoumarol.
Acenocoumarol Ciprofibrate	The risk or severity of bleeding can be increased when Ciprofibrate is combined with Acenocoumarol.
Acenocoumarol Simfibrate	The risk or severity of bleeding can be increased when Simfibrate is combined with Acenocoumarol.
Acenocoumarol Ronifibrate	The risk or severity of bleeding can be increased when Ronifibrate is combined with Acenocoumarol.
Acenocoumarol Aluminium clofibrate	The risk or severity of bleeding can be increased when Aluminium clofibrate is combined with Acenocoumarol.